Polaris Venture Management Co. V, L.L.C. - Q1 2021 holdings

$77.1 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 8 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .

 Value Shares↓ Weighting
FATE  Fate Therapeutics, Inc.$46,987,000
-9.3%
569,8890.0%60.92%
-9.9%
LYRA  Lyra Therapeutics, Inc.$12,759,000
+1.7%
1,100,8520.0%16.54%
+1.0%
SELB  Selecta Biosciences, Inc.$12,550,000
+49.3%
2,773,4790.0%16.27%
+48.4%
XFOR  x4 Pharmaceuticals Inc.$2,682,000
+33.9%
311,4920.0%3.48%
+33.1%
LIFE  Atyr Pharma Inc.$581,000
+14.6%
130,5720.0%0.75%
+13.7%
DARE  Dare Bioscience, Inc.$551,000
+26.1%
326,2410.0%0.71%
+25.3%
GNCA  Genocea Biosciences, Inc.$535,000
+11.9%
197,3450.0%0.69%
+11.2%
PULM  Pulmatrix, Inc.$478,000
+11.7%
359,4410.0%0.62%
+10.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-05-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings